Peter Greenberg, MD
Hematology · Stanford, CANPI 1912033978
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,020 of the $8,081 with a category attached, or 99.3%. 6 manufacturers reported payments, led by Novartis at 37.1% of the total. Reporting peaked in 2020 at $5,020 and has fallen 99.7% since, to $16 in 2025.
Across 6 payments — averaging $1346.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Gilead$3K
- Bristol Myers Squibb$2K
- Blue Earth Diagnostics$23
- Telix Pharmaceuticals$21
- Sumitomo Pharma America, Inc.$16
Across 60 payments — averaging $18,023 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$460K
- Novartis$271K
- Gilead$231K
- Genentech, Inc.$119K
What the payments were for
- Consulting fees$8,02099%
- Food & beverage$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $3,000 |
| Gilead | 1 | $2,770 |
| Bristol Myers Squibb | 1 | $2,250 |
| Blue Earth Diagnostics | 1 | $23 |
| Telix Pharmaceuticals | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONUREG$2,250
How this compares
$8,081 in reported general payments places this provider in the 55th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Stanford
- Everett MeyerStanford$2.1M
- Deepu MadduriStanford$348K
- Surbhi SidanaStanford$170K
- Michaela LiedtkeStanford$112K
- Sydney LuStanford$110K
- Saurabh DahiyaStanford$94K
- David MiklosStanford$90K
- Lori MufflyStanford$87K
- Ravindra MajetiStanford$58K
- Robert NegrinStanford$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.